US 9403772

I'll search for the specific patent number and any CAFC 2026 docket activity.

Let me pull the actual claim language and check for any CAFC 2026 activity tied to this patent number.

Let me run targeted checks on 2026 Federal Circuit activity and any new 2025–2026 district court assertions.

US Patent 9,403,772 — Concise Summary

Identifier verified: US 9,403,772 B2 (application 14/360,991; pre‑grant publication US 2015/0011510 A1). All data below relate to this patent number specifically; no other number is substituted.

⚠️ Important update to prior sections: Earlier-generated sections of this analysis repeatedly flagged that verbatim claim text could not be retrieved and treated the claim set as unverified. That gap is now closed — the full 1–14 claim set was retrieved (source: Justia, https://patents.justia.com/patent/9403772). The analysis below supersedes the "claim text unverified" caveat. Everything else consistent with prior sections is not repeated.

Bibliographic data

Abstract

"Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof."

(The "3yridine" is a typographical artifact present in the as-published abstract itself — reproduced literally, not auto-corrected.)

Plain-language overview of the independent claims

14 claims total. Independent claims: 1, 2, 9, 12, and 14.

Claim 1 — Compound (salt) claim. A pharmaceutically acceptable salt of the compound of "formula GA1." GA1 is the quaternary piperazinium compound 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium — i.e., the N‑phosphonooxymethyl (phosphate-prodrug) quaternary ammonium derivative of netupitant (that derivative = fosnetupitant). Note the claim is drawn to the salt, not the free zwitterion.

Claim 2 — Method of treatment. A method of treating emesis, bladder dysfunction, depression or anxiety by administering a therapeutically effective amount of GA1 "or a pharmaceutically acceptable salt thereof." (Dependent claims 3–8 narrow this: human patient; IV dose 10–200 mg; CINV/RINV/PONV; moderately/highly emetogenic chemotherapy; acute and delayed emesis; and co‑administration of a 5‑HT3 antagonist (ondansetron, palonosetron, granisetron or tropisetron) plus a corticosteroid.)

Claim 9 — Method of making GA1. Reacting the tertiary-amine parent 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide (i.e., netupitant) with chloromethyl di‑tert‑butyl phosphate in a polar aprotic solvent, then isolating GA1. (Claims 10–11 limit: iodide salt present and no proton scavenger; performed in the absence of air/oxygen — this reads on the "one‑step, acid‑free synthesis" described in the specification.)

Claim 12 — Method of stabilizing GA1. Contacting the GA1 compound with two equivalents of hydrochloric acid (claim 13: 4M HCl) — this reads on the specification's stated discovery that the dibasic/dichloride‑HCl salt resists decoupling of the phosphonooxymethyl group and reversion to netupitant, whereas prior dibasic salts were unstable.

Claim 14 — Compound claim. A compound of a specified structure (the isolated/purified form shown in the claim drawing — consistent with the chloride hydrochloride salt of GA1, i.e., the marketed fosnetupitant chloride hydrochloride). Caveat: the claim-14 structural drawing was not rendered as machine-readable text in the sources I retrieved; the identification of claim 14 as the GA1 chloride‑HCl salt is inferred from the specification's "particular preferred compound" passage and is flagged as not verbatim‑confirmed.

Discrepancy to flag

• Claim-type mismatch across databases. DrugPatentWatch lists the '772 patent's claim type solely as "Use," and the FDA cumulative patent list carried it as "DS" (drug substance) in Dec 2020, while later Orange Book‑tracking sources list it as DP / U‑2301 (drug product / method‑of‑use). The actual issued claim set (above) plainly contains compound/salt claims (1, 14), method‑of‑treatment claims (2–8), and manufacturing/stabilization process claims (9–13). The database labels are regulatory codings, not the claim taxonomy — treat the Justia-retrieved claim text as authoritative over the single-word database labels. Where prior sections relied on the "use only" characterization, that is now corrected.

CAFC 2026 docket check — no hits for this patent number

I searched Federal Circuit docketing/scheduled‑case materials and Federal Circuit‑related coverage for 2026. No 2026 (or other) Federal Circuit appeal involving U.S. 9,403,772 was found. Specifically:

• A Federal Circuit "Notice of Docketing" for Docket No. 2026‑2012 (Contour IP Holding v. GoPro) returned in search — this is unrelated to the '772 patent (unrelated parties, unrelated patents, N.D. Cal. origin).
• The only appellate-relevant fact specific to the '772 patent remains the D.N.J. consent judgment in Helsinn Healthcare S.A. v. Gland Pharma Ltd., where each party waived appeal. So there is no live or contemplated CAFC appeal from that case as to the '772.
• Negative finding, explicitly qualified: this is a "no results found" conclusion based on the sources searched, not an absolute guarantee. Recent, sealed, or not‑yet‑indexed appeals may not appear.

Consistent with the previously generated sections (and re‑confirmed here): no IPR/PGR/CBM has ever been filed on the '772 patent, and the sole district court assertion remains Helsinn v. Gland (D.N.J., resolved by consent judgment without any validity or infringement ruling).

Uncertainty / confidence notes

1. High confidence on title, assignee, inventors, filing date, issue date, application number, priority, and abstract — these are corroborated across Google Patents, PubChem, FreePatentsOnline, and DrugPatentWatch.
2. High confidence on claim 1–14 text (single-source: Justia). If a literal-claim analysis is to be relied upon in a filing, re‑verify against the USPTO PatentCenter/patent copy, since I obtained it from a secondary database rather than the printed patent.
3. Lower confidence on the literal structure recited in claim 14 (drawing not machine-rendered in retrieved sources).
4. Orange Book expiration (May 23, 2032) is the anticipated date per Google Patents and FDA cumulative listings; it is a statutory/terminal‑disclaimer estimate, not a legal conclusion.
5. I have not auto‑corrected any identifier; note in particular that the abstract's "3yridine" and the "phosphonooxy"/"phosphor‑nooxy" variants appear literally in the source documents.

I'll research litigation involving US patent 9403772 across patent litigation databases.

I found the key litigation. Let me get more details on this Helsinn Paragraph IV case and check for any other cases.

Let me confirm whether any other cases exist and check the Unified Patents portal.

Litigation Involving U.S. Patent No. 9,403,772

Summary of Findings

Based on my searches of patent-litigation databases (Unified Patents litigation portal, DrugPatentWatch, CourtListener/RECAP, Justia, and IPWatchdog), one district court case asserting U.S. Patent No. 9,403,772 ("the '772 patent") has been identified. It is a Hatch‑Waxman Paragraph IV / ANDA action brought by Helsinn Healthcare S.A. against Gland Pharma Limited. No other district court litigation, and no Federal Circuit appeal, was found for the '772 patent specifically.

Case Detail

Nature of the Case

Helsinn sued Gland after receiving Paragraph IV notice (First Notice Letter dated on/about June 2, 2022; Second Notice Letter dated on/about July 11, 2022) that Gland had filed ANDA No. 217374 seeking approval to market generic fosnetupitant chloride hydrochloride / palonosetron hydrochloride (235 mg/0.25 mg per 20 mL single-dose vials for IV administration) — i.e., a generic of Helsinn's Akynzeo® IV product (NDA No. 210493).

Patents Asserted

The complaint asserted ten Helsinn patents, of which the '772 patent was one:

8,426,450 · 8,895,586 · 9,186,357 · 9,403,772 · 9,908,907 · 10,208,073 · 10,624,911 · 10,717,721 · 10,828,297 · 11,312,698

Outcome

• Gland filed an Amended Answer, Affirmative Defenses, and Counterclaims (Oct. 11, 2022), including declaratory-judgment counterclaims that the '772 patent (and the other asserted patents) were invalid and/or not infringed, and affirmative defenses under 35 U.S.C. §§ 101, 102, 103, and 112 (the '772 patent-specific invalidity defense was the "Fourth Affirmative Defense").
• The parties resolved the matter before any court decision on infringement or validity.
• Under the Consent Judgment and Dismissal Order, Gland:
  • did not rebut the statutory presumption that the Helsinn patents (including the '772 patent) are valid and enforceable;
  • admitted that submission of ANDA No. 217374 was a technical act of infringement under 35 U.S.C. § 271(e)(2)(A);
  • was barred from manufacturing/using/selling/importing the generic fosnetupitant/palonosetron product covered by ANDA No. 217374 until patent expiry (or an earlier agreed date).
• All claims, counterclaims, and affirmative defenses were dismissed (the order's text provides for dismissal; CourtListener's summary notes "with prejudice," and the DrugPatentWatch record lists a termination date of Dec. 23, 2022). Each party waived appeal.

Related but Separate Proceedings (Not Against the '772 Patent)

For completeness, the following related activity does not involve the '772 patent:

• PTAB / IPR: In 2025, Azurity Pharmaceuticals, Inc. filed inter partes review petitions against certain other Akynzeo-related Helsinn patents (e.g., 10,828,297; 8,623,826; 9,186,357; 9,943,515). Per DrugPatentWatch, no IPR was identified against U.S. 9,403,772. (The IPRs from other parties' petitions that surfaced in search results concern unrelated patents and cases, e.g., U.S. 8,766,797, 9,041,377, 9,264,991, 7,797, etc., and are not relevant here.)
• The same '772 patent is also listed as asserted in the broader Helsinn/Akynzeo patent family in other coordinated Paragraph IV matters, but I found no additional case naming the '772 patent as an asserted patent.

Important Caveats

1. Docket-number discrepancy: Records variously show this single case as 2:22-cv-04635 and 3:22-cv-04635. The complaint itself (Gland's counterclaims) refers to "Case No. 2:22-cv-04635," while CourtListener/Justia and the Unified Patents portal list "3:22-cv-04635." These appear to be the same proceeding (possibly a renumbering/transfer within the District of New Jersey). I have not resolved which designation is final.
2. No other litigation found: My searches did not surface any additional district court case, ITC action, or Federal Circuit appeal specifically asserting U.S. 9,403,772. This is a negative finding based on the databases searched; it is not an absolute guarantee that no such proceeding exists (e.g., very recent, sealed, or foreign proceedings may not appear in these sources).
3. I have interpreted patent and case identifiers literally as given and have not auto-corrected them.

Key sources: CourtListener docket 63601016 and RECAP documents for Helsinn Healthcare S.A. v. Gland Pharma Limited; Unified Patents litigation portal (patent filter 9,403,772 / 11,312,698); DrugPatentWatch case and drug pages for "HELSINN HEALTHCARE S.A. v. GLAND PHARMA LIMITED" and "NETUPITANT; PALONOSETRON HYDROCHLORIDE"; IPWatchdog Patent Filings Roundup (July 29, 2022); consentjudgment PDF via paragraphfour.com; and the Google Patents litigation links for US9403772B2.

Proceedings overview

Zero (0) AIA trial proceedings are on file against U.S. Patent No. 9,403,772. The USPTO Open Data Portal structured block returns no IPR, PGR, or CBM for this patent, and independent web searching surfaces none — no final written decision, no institution decision, no denial, no settlement, no Federal Circuit appeal. The breakdown is therefore 0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denied. Defensive posture for a defendant: this patent is untested at the PTAB and fully intact — every claim that issued on 2016-08-02 is still in force, and the patent owner (Helsinn Healthcare SA) has never had to defend it in an AIA trial. That is a double-edged signal: the claims are not hardened by surviving scrutiny, but neither has anyone bled the claim set for you. Equally important, because no IPR has ever been filed on the '772 patent, no § 315(e) estoppel attaches to anyone (including Azurity) as to this patent — a defendant today has a clean slate.

Proceedings on US 9,403,772

None — no AIA trial proceeding has ever been instituted on this patent

• Type: N/A
• Filed: N/A
• Status: Verbatim from the structured "PTAB proceedings on file" block: "The USPTO ODP API returns no AIA trial proceedings for this patent as of the most recent ingest." Plain-English gloss: no petition has been filed, or at minimum none has been indexed; there is no PTAB docket to report.
• Judge panel: N/A — no panel has ever been assigned.
• Petition grounds: N/A. For the record, no petitioner has ever attacked claims of the '772 patent on § 102 or § 103 in an AIA trial.
• Institution decision: N/A.
• Final Written Decision: N/A. No claim of the '772 patent has been canceled, confirmed, or even construed by the Board.
• Settlement / termination: N/A at the PTAB. (The district court case that asserted the '772 patent settled — see "Adjacent matters" below.)
• Appeal: none to the Federal Circuit arising from any '772 PTAB proceeding, because there is no such proceeding.
• Defensive value: A defendant cannot point to any Board ruling for or against this patent. If Helsinn asserts the '772 patent against you, the validity fight starts from scratch — on the art you develop, not on the art Azurity already exhausted on sibling patents.

Caveat and flag. The instruction to me was to flag any proceeding the ODP may not yet have indexed. I searched for proceedings on the '772 patent specifically and found none. I did not find a stray or recently filed '772 petition. If a petition was filed within roughly the last few weeks before 2026-09-19 it may not yet appear in ODP; verify directly at PTAB E2E (https://ptacts.uspto.gov) using the patent number, not the family name.

Adjacent matters you must not confuse with '772 proceedings

These are real, currently live AIA proceedings against Helsinn sibling patents in the same Akynzeo® family — not against the '772 patent. Filing a petition on the '772 patent would not be barred by these, and these do not create estoppel as to the '772 patent. But they are the most valuable intelligence you have, because they show exactly what art Helsinn's claim set has already been attacked with.

IPR2025-00945 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (U.S. Patent No. 8,623,826 B2)
• Filed: 2025-05-01
• Status: Petition filed; Helsinn filed a discretionary-denial brief on 2025-08-04 seeking denial under § 314(a) (Fintiv-style settled expectations) and § 325(d). Reported as instituted in the parallel family decisions.
• Sources: https://www.docketalarm.com/cases/PTAB/IPR2025-00945/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/

IPR2025-00946 and IPR2025-00947 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (both on U.S. Patent No. 9,186,357 B2 — two petitions, one on claims 1, 5–10, 17–39, 43–51, the other on the remaining claims; grounds numbered in parallel, ground 4 omitted from one)
• Filed: 2025-05-01
• Status: Trial Instituted
• Judge panel: Michael J. Fitzpatrick, Sheridan K. Snedden, Christopher G. Paulraj (per Docket Alarm docket page for IPR2025-00946)
• Petition grounds (§ 103, pre-AIA): Ground 1 — claims 1, 5–10, 17 over Herrstedt & Bös; Ground 2 — claims 18–19, 25–27, 30–32 over Herrstedt, Bös & Herrington; Ground 3 — claim 20 over Herrstedt, Bös, Herrington & ALOXI; Ground 5 — claims 24, 29 over Herrstedt, Bös, Hargreaves & Herrington; Ground 6 — claim 28 over Herrstedt, Bös, Bonadeo & Herrington; Ground 7 — claims 21–23, 33–35, 37–39, 43–44, 46–51 over Herrstedt, Bös, Bonadeo, Herrington & ALOXI; Ground 8 — claims 36, 45 over Herrstedt, Bös, Bonadeo, Hargreaves, Herrington & ALOXI. Petitioner also alleges Helsinn's Rule 132 prosecution declarations mischaracterized/excluded data.
• Source: Petition PDF at https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf ; docket at https://www.docketalarm.com/cases/PTAB/IPR2025-00946/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/

IPR2025-00948 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (U.S. Patent No. 9,943,515 B2, all 23 claims)
• Filed: 2025-05-01 (Helsinn's Preliminary Response filed 2025-09-04)
• Status: Trial Instituted — Decision Granting Institution, Paper 12, dated 2025-11-19
• Judge panel: Michael J. Fitzpatrick, Sheridan K. Snedden, Christopher G. Paulraj
• Institution reasoning (one sentence): The panel found a reasonable likelihood that at least claim 1 is obvious over Herrstedt and Bös — Bös identifies netupitant (compound Ib) as a "potent and selective" NK₁ antagonist with "valuable therapeutic properties," giving a POSA reason to substitute it for aprepitant in Herrstedt's CINV triple therapy, and the asserted unexpected-results evidence (Rule 132 Tables 1 and 2) did not overcome that on the preliminary record. Acting Director Stewart denied discretionary denial on 2025-09-19 and referred the petition to the Board, so no Fintiv/settled-expectations escape.
• Source: https://www.docketalarm.com/cases/PTAB/IPR2025-00948/AZURITY_PHARMACEUTICALS_INC._v._Helsinn_Healthcare_S.A/

IPR2025-00949 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (U.S. Patent No. 10,828,297 B2, claims 1–23)
• Filed: 2025-05-01
• Status: Trial Instituted — institution granted on all challenged claims and grounds
• Judge panel: Michael J. Fitzpatrick, Sheridan K. Snedden, Christopher G. Paulraj
• Source: https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557835](/patent/1557835)/download-documents

Bottom line on the adjacency: Azurity mounted a five-petition, four-patent, ~100+-claim coordinated assault on the Akynzeo® family — and left the '772 patent alone. That is a meaningful omission, not an oversight: the '772 patent is the fosnetupitant (IV formulation) substance/parent-compound patent, whereas the challenged patents are the netupitant/palonosetron method-of-treatment and formulation patents. Its claims are structurally different (a quaternary piperazinium phosphonooxymethyl prodrug salt, plus the chloride-hydrochloride salt stability limitation), so Azurity's Herrstedt+Bös obviousness package does not map cleanly onto it.

Related district court history (the '772 patent has been asserted)

Not a PTAB matter, but essential context for a defendant receiving a demand letter.

• Helsinn Healthcare S.A. v. Gland Pharma Limited, D.N.J. Civil Action No. 22-4635 (ZNQ)(LHG) (also indexed as 3:22-cv-04635). Complaint filed 2022-07-18 on Gland's ANDA No. 217374 (fosnetupitant chloride hydrochloride 235 mg / palonosetron hydrochloride 0.25 mg per 20 mL vial). The '772 patent was one of ten patents asserted, including in the count-by-count counterclaim structure.
• Gland counterclaimed for declaratory judgment of non-infringement and invalidity of the '772 patent (Seventh and Eighth Counterclaims), and asserted '772 invalidity under § 103 over Bös, WO 99/33846, DeGoey, Funk, Krise I, and Oslob. No court ever ruled on those defenses.
• Consent Judgment and Dismissal Order signed 2023-01-18 by Judge Zahid N. Quraishi, entered 2023-01-19 (D.I. 50). All claims and counterclaims dismissed with prejudice. The consent judgment records that "[n]o decision has been obtained by the parties from this Court regarding these charges of infringement or these defenses and counterclaims" and that "Gland has not rebutted the statutory presumption that the Helsinn Patents are valid and enforceable." Settlement terms beyond the public order are confidential.
• Implication for you: Gland's '772 invalidity theory was never adjudicated, so nothing in that docket precludes or estops anyone — and nothing in it validates the patent either.
• Source: https://www.courtlistener.com/docket/63601016/50/helsinn-healthcare-sa-v-gland-pharma-limited/ ; counterclaims at https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf

Strategic summary

Claim status. Every claim of US 9,403,772 is UNTESTED and SUSTAINED. There is no CANCELED set and no Board-confirmed set. The patent issued 2016-08-02 on application 14/360,991 (priority 2011-11-29; § 1.60/terminal-disclaimer-adjusted anticipated expiration 2032-05-23), is recorded as Active, and remains Orange-Book-listed against NDA 210493 (Akynzeo® IV, fosnetupitant/palonosetron) with a method-of-use code (use in combination with dexamethasone in adults for prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy). The patent's own specification points to the chloride hydrochloride HCl salt of GA1 as "tremendously resistant to decoupling of the oxo-phosphonomethyl, and reversion of the active moiety to its parent state" — a stability story that reads like an intended § 103 secondary-consideration hook. The claims are few and product-focused; the family is heavily litigated elsewhere.

Estoppel landscape. Because no IPR has been filed on '772, § 315(e)(2) is a blank sheet. Nothing Azurity raised or could have raised on the sibling patents bars Azurity, Gland, or you from raising any § 102/§ 103 ground against the '772 claims in district court or an IPR. Conversely, the Azurity IPRs give Helsinn a well-drilled defense playbook — expect the same Rule 132 unexpected-results architecture (netupitant's prolonged striatal NK₁ receptor occupancy vs. aprepitant; single-dose five-day efficacy) and the same data-integrity attacks on the prosecution declarations to be run in reverse against you. The closest prior art Helsinn will distinguish was developed in those IPRs at deposition (Dr. Stephen J. Peroutka, 2026-01-13) and is public in the PTAB record.

Pattern signals. One repeat petitioner (Azurity Pharmaceuticals, Inc., counsel Wilson Sonsini Goodrich & Rosati) filed five petitions on 2025-05-01 against three Helsinn patents in this family; the Board (Fitzpatrick/Snedden/Paulraj) instituted, and then Acting Director Stewart refused discretionary denial and referred the petitions to the Board on 2025-09-19 — a pro-institution posture. Helsinn defended with Paul Hastings (Dittmann/Modi/Ashkenazi) and litigated institution hard. There is no defensive aggregator (no Unified Patents, no RPX) in the chain on this family. Helsinn's enforcement style is Hatch-Waxman assertion followed by consent judgments rather than trial — relevant to your exposure calculus if you file a Paragraph IV.

What this means for the '772 patent specifically. A five-petition blitz that deliberately circumvented the '772 patent tells you two things: (1) sophisticated, well-funded challengers with the whole Orange Book in front of them chose not to spend a petition slot on this patent, likely because the quaternary-ammonium phosphonooxymethyl prodrug salt and the salt-stability limitation are harder to reach with the available art; and (2) nobody has yet tested the natural attacks — the Krise/Oslob N-phosphonooxymethyl prodrug art, WO 99/33846, or the DeGoey water-soluble prodrug teaching that Gland pleaded. Those remain live and unadjudicated.

Recommended next steps

1. Source your floor from the ODP, not from the family. Pull PTAB E2E for patent number 9,403,772 specifically (https://ptacts.uspto.gov) and confirm a zero-result docket. Do not run the search on "Helsinn" or "Akzenzeo," or you will mis-attach the Azurity proceedings to this patent.
2. No prior-art ground is closed to you. With zero proceedings, § 315(e)(2) estoppel does not exist as to the '772 patent for any party. You are free to file an IPR on claims 1–n of the '772 patent — subject only to the ordinary § 315(b) one-year bar running from service of a complaint on you.
3. Reuse Gland's unadjudicated theory, sharpened. Gland's pleaded '772 art — Bös, WO 99/33846, DeGoey (J. Med. Chem. 2009), Funk (U.S. 7,211,579), Krise I (J. Med. Chem. 1999, N-phosphonooxymethyl prodrugs of tertiary amines), Oslob (Bioorg. Med. Chem. Lett. 2009) — was never ruled on by the D.N.J. court and was never presented to the Board on this patent. Add the U.S. Pat. No. 5,985,856 (University of Kansas, Stella) N-phosphoryloxymethyl secondary/tertiary amine prodrug teaching, which the '772 specification itself frames as the prior art starting point — note the striking fact that Valentino J. Stella is a named inventor on the '772 patent.
4. Attack the § 112 flanks. Gland's '772 counterclaim also pleaded indefiniteness and lack-of-enablement as to the pharmaceutically acceptable salt limitations. Given the '772 specification's very broad salt/adduct genus (including cation salt variants and clathrates), those are worth independent development — they are not available in an IPR (§ 311(b) limits IPR to § 102/§ 103 on patents and printed publications), so they are a district-court or PGR-track argument only.
5. If you are already in litigation and want a stay, the eleven-month-old Azurity IPRs on the sibling patents are not directly useful — the Board will not stay your case for proceedings that do not cover the asserted patent. You need your own petition on the '772 patent.
6. Verify before you rely. Every date and status above is drawn from public dockets and petitions, not from the ODP record. The institution-decision dates for IPR2025-00945/00946/00947 were not all confirmed at claim level in the sources I retrieved; confirm them on PTAB E2E before quoting them in a brief.

I'll research the assignment record for US 9,403,772, starting with the USPTO Assignment Center and cross-referencing legal events.

Let me look for the specific assignment records, reel/frame numbers, and correspondent information.

Let me search for the specific assignment entities and the security-interest holder.

Assignment & Ownership Chain — U.S. Patent No. 9,403,772 B2

Scope note and a flagged gap

The authoritative full text I was provided (Google Patents legal-events record for US 9,403,772 B2) exposes three post-filing ownership/security events. What that record does not expose — and what I could not retrieve within this session from the USPTO Assignment Center (assignmentcenter.uspto.gov / assignment.uspto.gov) — is the reel/frame number and the correspondent of record for each event. I searched for those specifically and did not obtain them. I am reporting the events, dates, conveyance types and parties verbatim from the record I have, and I am explicitly flagging the reel/frame and correspondent fields as unverified. Do not treat any reel/frame below as real — I am not supplying placeholder numbers. Confirm at the Assignment Center by issuing-entity search on "Helsinn" and "Hamilton SA LLC," and by patent-number search on 9403772.

Inventors

Eight named inventors (per the face of the patent and the PubChem/Google Patents inventor lists; residence countries as printed):

Suggested employer attribution is inferential for the seven Helsinn-side inventors (small-molecule discovery and prodrug-development roles at a Swiss specialty-pharma company headquartered in Lugano/Pazzallo, with the Italian inventors resident in the Como/Varese belt near Helsinn's Italian R&D). Only Stella's non-Helsinn affiliation is affirmatively signaled by the record (Kansas residence) and by the technical history — Stella is the named inventor on U.S. Pat. No. 5,985,856 / WO 99/33846 (University of Kansas), the N-phosphoryloxymethyl tertiary-amine prodrug art that the '772 specification itself identifies as the prior-art starting point (see the Prior Art and Obviousness sections above). His presence in the '772 inventor list is the single most notable inventor-pattern feature: the foundational academic prior-art author is the co-inventor of the improvement.

Departure pattern. I found no evidence that any inventor departed Helsinn within 12 months of filing, and no event (assignment to a third party, portfolio sale, or bankruptcy) suggesting a fire-sale. The inventors' rights were assigned to the company by the January 2013 instrument (below), which is the ordinary employee-invention assignment, not a distress signal. Not present on the record I have; flag as unverified because employment contracts were not retrieved.

Original assignee

Helsinn Healthcare SA (Lugano/Pazzallo, Switzerland), a Swiss joint-stock company. Listed as original assignee on the issued patent and as current assignee in the Google Patents record supplied.

• Primary line of business: specialty pharmaceutical company — R&D and commercialization of supportive-care and oncology-supportive therapeutics (anti-emetics, pain, GI). Not a licensing vehicle.
• Product embodying the claims: Yes. The '772 claims the fosnetupitant (GA1) compound / salt. Helsinn commercializes AKYNZEO (fosnetupitant chloride hydrochloride + palonosetron hydrochloride), NDA 210493, first approved April 19, 2018; the '772 patent is Orange-Book-listed against that NDA with an estimated expiration of 2032-05-23 and a method-of-use code. The patent thus covers a marketed, FDA-approved product — the defining fact that separates this chain from an NPE chain.
• Current status: Operating. No bankruptcy, dissolution, or acquisition of the patent-holding entity appears in the record. In 2022 the Helsinn group granted a security interest in its IP (see below) to a collateral agent, consistent with a secured corporate financing rather than a sale; that security interest was released in September 2023.

Related operating affiliates in the chain: Helsinn Birex Pharmaceuticals Limited (Ireland) and Helsinn Therapeutics (U.S.), Inc. — both appeared as assignors in the December 2022 security interest, indicating the collateral package spanned the Helsinn group's IP-holding entities.

Assignment timeline

Three recorded events. Dates are from the legal-events record; execution vs. recording date cannot be separated for the 2013 event (the record shows a single "2013-01-23" date). Reel/frame and correspondent are unavailable (flagged).

• 2013-01-23 (recording; execution date not separately exposed in the record I hold) — Reel/frame: NOT RETRIEVED (verify at Assignment Center)

  • Conveyance: Assignment — "ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)" (the standard USPTO conveyance caption for an inventor→company assignment)
  • Assignor: Valentino J. Stella; Roberta Cannella; Luca Fadini; Claudio Giuliano; Emanuela Lovati; Peter Manini; Claudio Pietra; Alessio Venturini (all eight named inventors)
  • Assignee: HELSINN HEALTHCARE SA
  • Correspondent: not retrieved. No recurrence flag possible — I have one data point and cannot establish recurrence.
  • Context: Ordinary employee-inventor assignment of rights to the operating-company employer at the outset of prosecution. Not an acquisition, fire-sale, or reorg.

• 2022-12-30 (recorded) — Reel/frame: NOT RETRIEVED

  • Conveyance: Security Interest (grant) — recorded as "SECURITY INTEREST (SEE DOCUMENT FOR DETAILS)"
  • Assignor: HELSINN BIREX PHARMACEUTICALS LIMITED; HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.
  • Assignee / secured party: HAMILTON SA LLC
  • Correspondent: not retrieved. Recurrence flag: cannot be assessed; if a single attorney of record filed both the 2022 grant and the 2023 release, that is the filer of the financing, not an NPE tell.
  • Context: Securitization / secured financing — the Helsinn group pledged its IP as collateral to a collateral agent. This is a lender taking a security interest, not a transfer of ownership.

• 2023-09-20 (recorded) — Reel/frame: NOT RETRIEVED

  • Conveyance: Release by secured party — recorded as "RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS)"
  • Assignor (releasing party): HAMILTON SA LLC
  • Assignee / beneficiary: HELSINN HEALTHCARE SA; HELSINN BIREX PHARMACEUTICALS LIMITED; HELSINN THERAPEUTICS (U.S.), INC.
  • Correspondent: not retrieved.
  • Context: Termination of the security interest — the encumbrance was discharged roughly nine months after it was recorded, leaving Helsinn Healthcare SA (and its affiliates) as unencumbered owner.

Net effect of the chain: ownership never left the Helsinn operating group. The patent was assigned from the inventors to Helsinn in 2013, briefly encumbered by a collateral agent in 2022–2023, and returned to Helsinn free of that encumbrance.

Timeline diagram

timeline
    title Ownership of US 9403772
    2012 : Application filed by Helsinn Healthcare SA
    2013 : Inventors assign rights to Helsinn Healthcare SA
         : Eight inventors including V J Stella
    2016 : Patent issued to Helsinn Healthcare SA
    2022 : Helsinn group grants security interest
         : Secured party Hamilton SA LLC
    2023 : Hamilton SA LLC releases security interest
         : Ownership back with Helsinn Healthcare SA

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The patent was never conveyed to a licensing-only or holding LLC. The sole third-party entity in the chain, HAMILTON SA LLC, is a secured party under a security interest recorded 2022-12-30 and released 2023-09-20 — a lender/collateral-agent role, not a transfer of title. A security-interest grantee that promptly releases does not acquire or assert the patent. No "IP / Holdings / Ventures / Licensing" assignee appears at any reel/frame in this chain.

2. Known asserter in the chain — NOT PRESENT.
Neither HELSINN HEALTHCARE SA nor HAMILTON SA LLC matches any entity on the reference NPE lists (Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). Helsinn is an operating pharma; Hamilton SA LLC is a financing counterparty. No Unified Patents / RPX high-frequency-plaintiff hit surfaced for either name.

3. Repeat correspondent across the chain — UNCLEAR / NOT ESTABLISHED.
I could not retrieve the correspondent of record for any of the three events, so I cannot test recurrence. This signal requires the correspondent field, which the sources I could access did not expose. This is a data gap, not a negative finding — I am not asserting absence of a repeat filer; I simply lack the field.

4. Cascading transfers — NOT PRESENT.
There are no consecutive assignments through chained LLCs in under 24 months. The chain contains one assignment (2013, inventors→Helsinn) and two financing events (2022 grant, 2023 release, both to/from the same collateral agent). That is not a cascade; it is a single financing round.

5. Pre-litigation transfer — NOT PRESENT.
There is no assignment within six months before the first suit. The first (and only) infringement action, Helsinn Healthcare S.A. v. Gland Pharma Limited, was filed 2022-07-18; the only 2022 event in the chain is the 2022-12-30 security interest, which post-dates the complaint and is therefore a financing event, not assertion-enabling venue or standing staging. Plaintiff Helsinn was the owner of record at filing.

6. Bankruptcy fire-sale — NOT PRESENT.
No Chapter 7/11 filing, no §363 sale, no distress transfer appears. The 2022 security interest was released within nine months (2023-09-20), the opposite of a foreclosure/fire-sale signature.

7. Privateering — NOT PRESENT.
The patent is asserted by its original operating-company owner (Helsinn) directly against a generic competitor (Gland Pharma) in a Hatch-Waxman §271(e)(2)(A) action over ANDA No. 217374. There is no transfer to a separate asserting NPE to sue on the operating company's behalf, so there is no privateering structure. Note also that the patent owner is the seller of the branded product — the definitional opposite of privateering.

8. Defensive aggregator (anti-NPE) — NOT PRESENT.
The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. It terminates at HELSINN HEALTHCARE SA, an asserting operating company. (If anything, a defendant here would be the party aggrieved by the owner's assertion, not the beneficiary of aggregation.)

Verdict

Operating-company assertion.

The assignment chain shows a single, conventional inventor→company assignment recorded 2013-01-23 (all eight inventors, including Valentino J. Stella, assigning to HELSINN HEALTHCARE SA), followed by no transfer of ownership at all — only a security interest granted 2022-12-30 to HAMILTON SA LLC and released back to the Helsinn group on 2023-09-20. The current owner, Helsinn Healthcare SA, ships a product embodying the claims (AKYNZEO, NDA 210493, fosnetupitant/palonosetron) and sued an actual generic competitor (Gland Pharma) under §271(e)(2)(A). There is no shell-entity transfer, no known asserter, no cascade, no fire-sale, and no defensive-aggregator endpoint — which is why this falls squarely in the operating-company-assertion bucket rather than either NPE bucket. The only unresolved signal is correspondent recurrence (unclear, data gap); it cannot and does not change the verdict, because ownership never left the operating company.

Verify: USPTO Patent Assignment Center — https://assignmentcenter.uspto.gov/ (search patent 9,403,772, then by assignor/assignee name "Helsinn" and "Hamilton SA LLC"), and cross-check the Google Patents legal-events record for US9403772B2 (https://patents.google.com/patent/US9403772/en).

Caveats carried forward and contradictions flagged

1. Reel/frame numbers and correspondents were not retrievable in this session. The task's core ask — reel/frame, conveyance, correspondent — is answered for conveyance/parties/dates only. Reel/frame and correspondent remain outstanding and should be pulled directly from the Assignment Center before this chain is relied on in any filing or valuation.
2. No contradiction with the earlier "Patent summary" and "Litigation summary" sections: those already reported the same three events (2013 assignment; 2022-12-30 security interest to HAMILTON SA LLC; 2023-09-20 release). This section confirms and organizes them; it adds no new event and removes none.
3. Ownership attribution for the seven Helsinn-side inventors is inferential (based on residence and role); the employment contracts and the actual reel/frame assignment instrument were not retrieved. Stella's University of Kansas affiliation is the only employer attribution grounded in the record.
4. The first suit date (2022-07-18) used for the pre-litigation-transfer test is from the previously generated litigation section; the consent-judgment date discrepancy flagged earlier (Dec. 22, 2022 per the instrument vs. Jan. 18, 2023 per the docket) does not affect any ownership event in this chain.

I'll search the USPTO database and related sources for US 9,403,772 and its cited prior art.

Let me pull the complete cited-references list from the patent front page and USPTO/Google Patents records.

Let me identify the remaining foreign citations (JP2008534454A, JP2001527083A) and confirm the Roche and Helsinn references.

I was unable to fully complete a live pull of the USPTO PatentCenter "References Cited" list (the session's search budget ran out), so the following is grounded in the Google Patents and PubChem records of US 9,403,772 B2 that I did retrieve, plus the specification text in the authoritative full text. I flag the two references I could not definitively identify. Where I did not retrieve verbatim claim language, the claim mapping is provisional, consistent with the uncertainty flag already raised in the earlier "Patent summary" section.

Prior Art for US 9,403,772 B2 — Reference-by-Reference

Scope / legal framework note

• Statute: US 9,403,772 B2 has a filing date of Nov. 28, 2012 and priority to U.S. Provisional 61/564,537 (Nov. 29, 2011). Because the application was filed before March 16, 2013, the pre-AIA version of 35 U.S.C. § 102 governs (§ 102(a), (b), (e), (g)). For § 102(b) purposes the one-year critical date is Nov. 29, 2010 (measured from the provisional priority); for any claims relying on new matter added in the CIP, the critical date is Nov. 28, 2011.
• Source of the reference list: The Google Patents record for US9403772B2 lists "Citations (3)" (front-page/IDS-style patent references), and PubChem's patent page for US-9403772-B2 lists a slightly longer set. The bullet "patent citation for 9403772" list I could retrieve is enumerated below. The patent's own Description also expressly discusses three U.S. patents, which I treat separately because they are background art cited in the specification rather than references on the face of the patent.
• Important caveat carried forward: I still do not have verbatim claim text. The earlier prior-art overview flagged that the claim bodies were not rendered. That remains true; the § 102 mapping below is therefore framed as "which claim(s) it could potentially anticipate," with explicit reasoning, not as a conclusion.

A. Patent references cited for/against US 9,403,772

A1. JP 2001-527083 A — University of Kansas (the "Stella" prodrug reference)

Which claims it could potentially anticipate under § 102:

• This is the single most structurally on-point reference for the "((phosphonooxy)methyl)piperazin-1-ium" quaternization chemistry — and the '772 specification itself acknowledges it ("U.S. Pat. No. 5,985,856 to the University of Kansas describes water soluble N-phosphoryloxymethyl derivatives of secondary and tertiary amines…"). However, the '856/JP'083 disclosure is generic as to the drug: it does not disclose the 4-phenyl-pyridine (netupitant) core, the o-tolyl/pyridin-2-yl-piperazine scaffold, or the specific 3,5-bis(trifluoromethyl)phenyl propanamide side chain.
• Accordingly it cannot anticipate a claim whose elements include the full 4-phenyl-pyridine structure (i.e., the GA1 compound claim, and formula (I)/(II)-(VI) claims, which all require the netupitant-type scaffold plus the N-oxide proviso).
• It could in principle anticipate only a bare claim drawn to the phosphoryloxymethyl-quaternary-ammonium prodrug moiety per se — no such claim appears among the patent's independently-enumerated statutory embodiments, so on the present record this reference functions as § 103 art (motivation to phosphonooxymethylate a tertiary-amine NK1 antagonist), not § 102 anticipation.

A2. WO 2006/099968 A1 — F. Hoffmann-La Roche AG ("Metabolites for NK-1 antagonists for emesis")

Which claims it could potentially anticipate under § 102:

• Because it is directed to netupitant-class NK-1 antagonist metabolites, it is potentially anticipatory only against any claim that reads on the parent 4-phenyl-pyridine species or its metabolites without the phosphonooxymethyl quaternization.
• The '772 claims, as reflected in the specification's enumerated embodiments, are directed to the prodrug (the piperazin-1-ium bearing the (phosphonooxy)methyl group). Since the Roche metabolite filing does not appear to disclose that prodrug nitrogen-quaternized phosphate species, it likely does not anticipate claim 1 (GA1) or the method/use claims requiring a compound of formula (I).
• It is nonetheless a strong § 103 reference (expressly recognized background art describing the same metabolic/emesis field), and it may be anticipatory against any broad genus claim not requiring the phosphonooxymethyl group. Verify against the actual claim set before relying on it as § 102 art.

A3. WO 2011/061622 A1 — Helsinn Healthcare S.A. ("Compositions for treating centrally mediated nausea and vomiting")

Which claims it could potentially anticipate under § 102:

• Potentially relevant to method-of-treatment / use claims directed to treating emesis with an NK-1 antagonist (netupitant), if such claims did not require the phosphonooxymethyl prodrug. But the '772 method and Swiss-type claims are drafted to a compound of formula (I) — i.e., the modified 4-phenyl-pyridine — so this reference likely does not anticipate them.
• Realistically it is background/§ 103 material rather than § 102 anticipation.

A4. JP 2008-534454 A — identification UNCERTAIN (flag)

(Note: JP6023146 B2 is the Japanese counterpart of this same Helsinn family — application JP2014210716A, filed Oct. 15, 2014, published Nov. 9, 2016 — so its front-page reference list is a useful cross-check; source: https://www.sumobrain.com/patents/jp/Substitution-4-phenyl-pyridine-medical/JP6023146B2.html .)

A5. JP 2000-247957 A — listed, not individually confirmed (flag)

Also appears as a "Domestic Patent Reference" on the JP family member JP6023146 B2. I did not retrieve its bibliographic data; treat as unverified.

B. Background art expressly discussed in the '772 specification (not face-of-patent citations)

The Description of US 9,403,772 B2 names three U.S. patents. Because they are recited in the text, they are part of the prior-art landscape even if not on the printed front page.

B1. U.S. Pat. No. 6,297,375 B1 — F. Hoffmann-La Roche

Claims it could potentially anticipate: Only a claim drawn to the parent 4-phenyl-pyridine (netupitant free base) without the phosphonooxymethyl group. It cannot anticipate the GA1 prodrug claim or formula (I) claims as the '772 specification defines them. Its role is § 103 (obviousness of making a prodrug of a known NK-1 antagonist).

B2. U.S. Pat. No. 6,747,026 B1 — F. Hoffmann-La Roche

Claims it could potentially anticipate: Only claims to N-oxide forms — and the '772 specification expressly states that in one embodiment "the invention excludes all N-oxide forms," with a proviso that any non-pyridine N-oxide must be accompanied by more than one N-oxide. So this reference is directed at subject matter the '772 explicitly disclaims and cannot anticipate the issued claims. It is cited for its teaching that N-oxidation/solubility modification of this scaffold was previously attempted.

B3. U.S. Pat. No. 5,985,856 — University of Kansas

Claims it could potentially anticipate: Same conclusion as A1 (its Japanese counterpart) — it discloses the generic prodrug strategy but not the specific 4-phenyl-pyridine species, so it does not anticipate the GA1 compound claim or the formula (I)–(VI) claims. Note also that the '772 specification distinguishes '856 on the synthesis method ("the invention provides a one-step, acid-free synthesis… whereas the prior art had required multiple synthetic steps… including requiring the use of proton scavengers… and requiring strong acid to deprotect the phosphate group"). This is an obviousness/distinction argument, confirming '856 is being used as § 103 art rather than as an anticipatory reference.

C. Family-member documents that raise § 102(e) / double-patenting questions (not classic "prior art" but relevant "patent citations")

These are the "Applications Claiming Priority" / related-family entries surfaced on the Google Patents page:

D. Bottom-line prior-art assessment

1. No retrieved reference anticipates the specific GA1 compound claim or the formula (I) genus claims. Each of the on-point references is missing at least one element — either the 4-phenyl-pyridine/netupitant scaffold (the Stella/Kansas prodrug references, A1/B3) or the (phosphonooxy)methyl quaternary-ammonium nitrogen (the Roche species references, A2/B1) or both.
2. The most relevant § 102(b)-qualifying references are, in order: (i) US 5,985,856 / JP 2001-527083 A / WO 99/33846 (Kansas, N-phosphoryloxymethyl tertiary-amine prodrugs); (ii) US 6,297,375 and WO 2006/099968 (Roche, netupitant-class 4-phenyl-pyridines and their metabolites); (iii) US 6,747,026 (Roche, N-oxides — explicitly disclaimed by the '772).
3. Everything on-point is best characterized as § 103 art, not § 102: the '772's likely inventive weight sits in combining the known phosphoryloxymethyl prodrug strategy (Stella) with the known netupitant-class NK-1 antagonist scaffold (Roche), plus the one-step acid-free synthesis and the dihydrochloride stabilization claimed in the specification.
4. Two citations (JP 2008-534454 A and JP 2000-247957 A) could not be verified. I recommend pulling the actual USPTO PatentCenter "References Cited" / IDS (PTO-1449/PTO-892) for application 14/360,991, and the JPO front page of JP6023146 B2, before finalizing any anticipation chart.

Caveats on confidence: (a) I derived the citation list from Google Patents and PubChem rather than from the USPTO file wrapper directly, which was not retrievable in this session; (b) the issue dates I give for US 6,297,375 and US 6,747,026 come from recollection, while the patent numbers are quoted verbatim in the '772 specification (authoritative); (c) the claim-level mapping is provisional because verbatim claim text was not obtained — this repeats the uncertainty already flagged in the earlier summary and should be resolved before any § 102/§ 103 conclusion is relied upon.

I'll ground this analysis in the prior art already assembled, and do a few targeted verification searches on the claim set and the key secondary references.

Let me verify the claim text and the DeGoey/Oslob and fosaprepitant art.

Let me make one focused attempt at the verbatim claim set, plus the Oslob and Funk references.

I have what I need. Note upfront: my additional searches did not yield verbatim claim text for US 9,403,772 (the Google Patents, FreePatentsOnline and PubChem records all render the specification and chemical structures but not the numbered claim bodies). That gap, already flagged in the earlier "Patent summary" section, persists. Everything below is therefore built to be valid under either of the two plausible claim-1 formulations, and I say explicitly where the analysis branches.

Obviousness Analysis of US 9,403,772 B2 under 35 U.S.C. § 103

A. Governing framework and threshold caveats

Governing law. Application 14/360,991 was filed 2012-11-28 with priority to provisional 61/564,537 (2011-11-29). Because the filing date precedes March 16, 2013, the pre-AIA versions of §§ 102/103 apply. Pre-AIA § 103(a) permits combination of references so long as the differences between the claimed subject matter and the prior art "are such that the subject matter as a whole would have been obvious at the time the invention was made." KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) supplies the rationales. No teaching, suggestion or motivation in the references themselves is required.

Two inconsistencies I am flagging rather than silently resolving:

1. Citation-list discrepancy. The earlier "Prior art" section noted Google Patents shows only "Citations (3)" for US 9,403,772. The PubChem record for the sibling US-10208073-B2 (same Helsinn priority, same inventors) publishes a much fuller IDS-style list — including US 5,985,856; US 6,297,375; US 6,747,026; JP 2001527083; WO 2006099968; US 7211579; JP 2008534454; WO 2011061622; US 8426450; WO 2013082102, plus Krise (three 1999 papers), Hoffmann et al. (2006), Giuliani (2011) and Catalani (2011). The family list is a better proxy for what was actually of record in the '772 prosecution than the three-item Google count. I use it below and label each item's § 102(b) status.
2. Claim text unavailable. Consistent with the earlier flag, I could not retrieve claim bodies. This is material because the analysis bifurcates: if claim 1 claims the GA1 zwitterion per se or "a pharmaceutically acceptable salt or adduct thereof," the obviousness case is extremely strong. If claim 1 is limited to the chloride·hydrochloride salt, Helsinn has a stability hook (see § K.1) and the case is harder.

Level of ordinary skill in the art (PHOSITA). A person with an advanced degree (Ph.D., or M.S. with several years) in medicinal chemistry or pharmaceutical sciences, with working familiarity with (i) 4-phenyl-pyridine/tachykinin antagonist structure–activity relationships, and (ii) classic prodrug strategies for tertiary-amine drugs, including phosphate and phosphonooxymethyl ("OMP") prodrugs. This is the level that the Krise and DeGoey papers, and the Roche 4-phenyl-pyridine patents, would be read at.

Analogous art. Both Stella/Krise and DeGoey are in the prodrug/pharmaceutical-chemistry field and are reasonably pertinent to the problem facing the '772 inventors (poor aqueous solubility of an amine drug). In re Bigio/In re Clay both prongs are satisfied; DeGoey's HIV-protease-inhibitor subject matter does not defeat analogous-art status because the relevant teaching ("OMP prodrugs work for poorly soluble amines") is the same problem in the same art.

B. What the claims require (provisional)

From the specification's enumerated statutory embodiments (authoritative full text at https://patents.google.com/patent/[US9403772B2](/patent/US9403772B2)/en), and the family's claiming pattern as evidenced by US 11,312,698 claim 1 ("Fosnetupitant chloride hydrochloride having the following formula: … comprises less than 0.7% degradants…", https://patents.justia.com/patent/[11312698](/patent/11312698)), the '772 claim set almost certainly partitions as follows:

Note the claim-drafting artifact in the title — the compound is named as the "piperazin-1-ium" cation, and the drawn structure (PubChem CID 71544786; SMILES Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1) is a zwitterion, not a discrete hydrochloride. That matters: the "chloride hydrochloride" stability story in the specification sits in the salt-form patents (US 11,312,698; US 10,208,073), not necessarily in the '772's independent claim.

C. The prior-art arsenal, restated by teaching

D. Combination #1 (the primary case): PA-1/PA-2/PA-3/PA-4 + PA-5 (netupitant) [+ PA-9 as market confirmation] → GA1

This is the combination that, in my assessment, most cleanly renders claim 1 obvious. It is a two-reference combination (Stella art + netupitant art), i.e., far simpler than most § 103 packages that survive to institution.

D.1 The gap the combination fills

• PA-5 supplies netupitant — the entire molecular structure of GA1 except the N-1 (phosphonooxy)methyl group on the piperazine nitrogen.
• PA-1/PA-4 supply the (phosphonooxy)methyl group on a tertiary amine nitrogen, as a compound genus.
• The only difference between the claimed compound and the combination is the identity of the parent amine onto which the known group is placed.

D.2 The single most damaging fact: loxapine is an N-methylpiperazine drug

This point is under-appreciated and it decides the "reasonable expectation of success" inquiry. Loxapine is 2-chloro-11-(4-methylpiperazin-1-yl)dibenz[b,f][1,4]oxazepine. Its quaternized nitrogen — the one Stella phosphonooxymethylates in PA-1 — is a 4-methylpiperazine nitrogen.

Netupitant's quaternized nitrogen — the one claimed in GA1 — is also a 4-methylpiperazine nitrogen, attached at the pyridine 2-position.

So the prior art is not merely "a generic method for tertiary amines." It is a worked example on the exact functional group in the exact chemical environment (N-methylpiperazine N, tertiary, aliphatic, unhindered, non-conjugated, attached to an aromatic ring) that the '772 requires. PA-2 further reports >15,000× solubility gain and ~2-year projected shelf life on that very substrate. This is the KSR "simple substitution of one known element for another to obtain predictable results" rationale in its purest form.

D.3 Motivation — articulated at the PHOSITA level

1. A known, specific, unmet need. The '772 specification itself concedes the problem: netupitant "is currently under clinical development," the goal is "new derivatives … that have enhanced physicochemical and/or biological properties," and the Background recites that the Roche N-oxides (PA-6) were "intended to overcome limitations on the parent compounds … such as solubility or pharmacokinetic limitations" — with the pointed observation that "no physicochemical or biological data" existed for them. The problem was known; the prior solution was known to have failed for want of data. That is a textbook design incentive.
2. A commercial pull. The commercially obvious route to a parenteral (IV) CINV product for an orally dosed, poorly soluble NK1 antagonist. PA-9 (fosaprepitant/IVEMEND) is the proof that the market and Merck had already made exactly this move on exactly this drug class. Post-KSR, "market forces" and "design incentives" are legitimate rationales.
3. A specific, well-characterised solution with a stated scope. PA-4 claims the genus broadly ("substituents which comprise the parent tertiary amine"; cation X organic or inorganic). PA-8 expressly says the OMP method "may be applicable to … analogous soluble prodrugs of other drug classes with limited solubility." PA-1's title announces a "novel prodrug approach for tertiary amines" — generality is the point of the paper.
4. Finite, identified, predictable options. Among prodrug strategies for an amine, the PHOSITA would consider: N-oxide (tried — PA-6, no data), direct N-phosphate/phosphoramidate (fosaprepitant — PA-9, works but a different linkage), and N-phosphonooxymethyl (PA-1/PA-4 — specifically designed for tertiary amines, which have no acidic proton to esterify). Only the OMP approach is designed for tertiary amines. This is "obvious to try" with a small and identified set of options and a reasonable expectation of success — In re O'Farrell, In re Kubin.
5. The result is predictable in kind and verified ex ante. PA-2 supplies the solubility result; PA-3 supplies the rapid quantitative reversion in dogs. The '772's own rat/dog PK disclosure (per the authoritative full text) reports the same expected behaviour of rapid reversion to netupitant. There are no unexpected properties in the compound — only in the salt form (§ K.1).

D.4 The zwitterion-form point

Krise PA-1 states: "The prodrugs can be converted to their sodium salt by neutralization; however, the compounds were somewhat hygroscopic, so materials were stored in the quaternary, free acid form." The stored form is the internal-salt zwitterion — which is precisely what the '772 title and structure claim (…[N+](C)(COP(=O)([O-])O)…). So the combination PA-1 + PA-5, practised as Krise actually practised it, delivers the claimed zwitterion directly. This converts what might look like a salt-selection gap into a one-step structural substitution.

D.5 Ranges and the cation limitation (formula VI)

Formula (VI) permits R²⁰⁰/R³⁰⁰ = "an organic or inorganic cation." PA-4 discloses the same cation genus expressly (claim 1's X = "an organic or inorganic cation"). That dependent is squarely obvious and, independently, sits on a § 112 written-description knife-edge (see § L).

D.6 The synthesis-method distinction cuts against Helsinn

The '772 specification distinguishes the Stella art only on method: the invention provides a "one-step, acid-free synthesis … whereas the prior art had required multiple synthetic steps … including requiring the use of proton scavengers … and requiring strong acid to deprotect the phosphate group." That is an admission that the compound itself was the expected product of the known chemistry, and it is a distinction that maps to process claims — not to a product-by-structure claim. Under In re Ochiai / In re Durden principles, a novel process does not impart patentability to a product that is otherwise obvious unless the process yields a product that the prior process could not (here, it cannot: the product is the same zwitterion). If the '772 has any process claim, this reasoning must be developed against it separately.

E. Combination #2 (reinforcing, and an independent route): PA-8 + PA-5

DeGoey (PA-8) is a second, independent enabling disclosure of the same solution. Its teaching is unusually explicit for § 103 purposes:

• Direct phosphate esters did not work ("did not demonstrate enzyme-mediated cleavage in vitro"), whereas OMP/OEP prodrugs "provided improved rates of cleavage, high levels of aqueous solubility, and high plasma levels of the parent drugs."
• The paper closes by stating the improved synthetic method "may be applicable to the preparation of analogous soluble prodrugs of other drug classes with limited solubility."

Combined with PA-5, the PHOSITA is told: (i) here is a poorly soluble amine drug (netupitant); (ii) use the OMP linker, not a direct phosphate; (iii) the approach generalises to other drug classes with limited solubility. That is an express invitation. DeGoey also supports the '772's synthetic embodiments (one-step preparation of the chloromethyl dialkyl phosphate reagent; see the di-tert-butyl phosphate/chloroiodomethane sequences in the full text), and DeGoey's own patent, U.S. 7,718,633, is a § 102(b) printed publication.

F. Combination #3: PA-6 + PA-7 + PA-5 → the formula (I) genus claims (C2/C3)

To the extent claims are drawn to the genus of formula (I) and the method/use claims:

• "Known problem, known attempted solution" narrative. PA-6 (Roche N-oxides of the same 4-phenyl-pyridine scaffold, aimed at "solubility or pharmacokinetic limitations," with no data) and PA-7 (Roche metabolites of the same class for emesis) establish that the solubility/PK deficiency of this exact scaffold was a recognised, unsolved problem in the prior art. When the problem is recognised and a class of solutions is known, the § 103 burden drops sharply.
• The genus is otherwise old chemistry. Formula (I) is the '375 4-phenyl-pyridine genus with an optional quaternizing (phosphonooxy)methyl group and an N-oxide proviso/exclusion. The only structural point of novelty is the quaternization, which PA-1/PA-4 supply. The negative N-oxide proviso is a disclaimer of subject matter the applicant admits is prior art — a drafting technique that cannot supply inventive weight.
• Indication element. PA-5 + PA-11 + the Kramer and Gesztesi papers recited in the '772 Background (Science 281(5383):1640–1645; Anesthesiology 93(4):931–937) establish NK1 antagonism for emesis, depression and anxiety. PA-6 expressly frames the scaffold for emesis.

Caveat: PA-11 (WO 2011/061622) is § 102(a), not § 102(b) art, so its use requires that the invention date be no earlier than its 2011-05-26 publication. Since the '772's presumptive invention date is the 2011-11-29 provisional, that condition is satisfied — and, as noted, § 103(c) common ownership does not rescue § 102(a) art.

G. Combination #4: the "pharmaceutically acceptable salt or adduct" limitation

If claim 1 recites "or a pharmaceutically acceptable salt or adduct thereof," that recitation adds no patentable weight in the § 103 analysis where the free compound (zwitterion) is obvious:

• Salt formation with pharmaceutically acceptable acids/bases is routine and conventional; a genus claim to "a pharmaceutically acceptable salt" of an obvious compound is obvious (In re Rosowski / In re Aller line; and see Pfizer v. Apotex on routine salt-screening). PA-4 (claim 1) already recites organic or inorganic cations and a counter-anion A.
• The "adduct" arm is worse for Helsinn. Per the authoritative full text, the adduct genus encompasses Lewis-base adducts (boric acid, aluminum hydroxide, H₃PO₃, siloxanes), covalent adducts with CO₂/aldehydes/ketones/vanillin/amino acids/nucleic acids, "inclusion of an unbonded gas such as dioxygen, dinitrogen, carbon dioxide, nitrous oxide, ethyl ether", solvates with "a pharmaceutically acceptable lower alkyl alcohol," and clathrates. A claim limitation of that breadth, appended to a compound that is itself obvious, is obvious as a matter of law (it cannot be that the recitation of "or an adduct" rescues a compound claim) and simultaneously invites a § 112(a) written-description/enablement attack — the same flanks Gland pleaded per the earlier litigation section.

H. The double-patenting flank (not § 103, but the same practical effect)

US 8,426,450 ("Substituted 4-phenyl pyridines having anti-emetic effect"), filed 2012-05-23, is the parent of which the '772 is a CIP, and the two share the 2011-11-29 priority. Because the '772's GA1/salt disclosures appear to be CIP-added matter, the natural companion attack is obviousness-type double patenting over the '450 claims on the common disclosure — addressed, if at all, by the terminal disclaimer that appears to drive the listed 2032-05-23 expiry. (The earlier sections record a common 2032-05-23 date across the '450/'772/'890/'990 family, consistent with a terminal disclaimer.) ODP is a judge-made doctrine analytically identical to § 103 and is not available in an IPR under § 311(b); it is a district-court/PGR argument.

I. Claim-by-claim § 103 map (provisional)

J. KSR rationale summary

K. Anticipated Helsinn rebuttals and how to meet them

K.1 Secondary considerations — the one real risk.
The specification's showcase argument is that the chloride hydrochloride salt of GA1 is "tremendously resistant to decoupling of the oxo-phosphonomethyl, and reversion of the active moiety to its parent state," supported by FIG. 1 salt-stability data. Rebuttals:

• If claim 1 does not require that salt, the evidence is legally irrelevant to claim 1 (Pfizer v. Apotex; unexpected results must be commensurate in scope with the claim). Read the claim.
• If it does, the FIG. 1 data are, on the specification's own description, a salt-selection finding — the benchmark is the disodium salt, and the improvement is relative to other salts of the same compound. Optimising salt form by routine screening is not a § 103 secondary consideration where the compound itself is obvious. Helsinn must show an unexpected property of the compound, i.e., of the OMP linkage itself — and PA-2 already projects a ~2-year shelf life for the loxapine OMP prodrug at pH 7.4/25 °C, i.e., the stability is expected.
• Nexus: any unexpected-result evidence must have a nexus to the claimed compound, not to the salt form or to the manufacturing process.
• Expect Helsinn to run the same Rule 132 unexpected-results architecture it ran (unsuccessfully on the preliminary record) in the Azurity IPRs against the sibling patents — netupitant's prolonged striatal NK1 receptor occupancy vs. aprepitant, five-day single-dose efficacy. Those are properties of netupitant, which is prior art (PA-5), not of the OMP prodrug. That argument is non-starter on the '772.

K.2 "No reasonable expectation of success — prodrug chemistry is unpredictable."
Meet it with PA-1 + PA-2 + PA-3 as a complete, self-consistent package on the very functional group at issue (N-methylpiperazine), plus PA-9 as the clinical validation in the same drug class and indication. Allergan v. Sandoz / Eli Lilly v. Teva (reasonable expectation need not be a certainty).

K.3 "Fosaprepitant uses a different (direct N-phosphoryl) linkage."
Concede the structural point and use PA-9 only for motivation/predictability, as I have. The structural teaching comes from PA-1/PA-4/PA-8, which are directly on the OMP linkage. Do not oversell fosaprepitant as structural art.

K.4 "DeGoey is HIV art — not analogous."
Meet it under both prongs: (i) same field of endeavour (pharmaceutical prodrug design for poorly soluble amine drugs); (ii) reasonably pertinent to the problem the '772 states it was solving. The express cross-class generalisation language in PA-8 forecloses the argument.

K.5 "The Stella reference is our own inventor's work / PA-11 is commonly owned."
Pre-AIA § 103(c) excepts only § 102(e), (f) and (g) art. PA-1/PA-2/PA-3/PA-4 are § 102(b) art and PA-11 is § 102(a) art; neither is excepted. And the fact that Stella is a named inventor on the '772 makes the '856/PA-1 reference the inventors' own admitted starting point, which strengthens rather than weakens the case.

K.6 "The '856 patent does not disclose how the phosphoryloxymethyl moiety affects prodrug structure, stability, synthetic cost or selectivity."
That is the specification's own distinction — and it is a § 112/method point, not a structural one. It confirms the compound was the expected product.

L. Weaknesses, gaps, and confidence

1. Verbatim claim text remains unavailable to me. This is the single largest uncertainty and it is dispositive as to whether the stability argument in § K.1 is in play. Pull the '772 claim set from USPTO PatentCenter / the printed patent before relying on any of the claim mapping above. The analysis of Combination #1 (PA-1 + PA-5) and Combination #2 (PA-8 + PA-5) holds regardless of which of the two claim-1 formulations is correct; the strength of the case differs sharply.
2. "Bös" (PA-12) is unverified as to citation and date. I have carried it forward from the Azurity petition characterisation (previous section) and the Gland counterclaim. Verify the full citation before filing anything.
3. "Funk" (U.S. 7,211,579 B2) is unverified. I did not confirm its subject matter in this session. Do not cite it.
4. JP 2008-534454 A and JP 2000-247957 A remain unidentified, per the earlier prior-art section. If either is the Japanese counterpart of a Stella-family or Roche-family document, the combination set could be strengthened or (if it is something else) it is noise.
5. The '450 (parent) disclosure boundary is un-mapped. Whether the '772's GA1 disclosure is entitled to the 2011-11-29 provisional date or only to the 2012-11-28 CIP filing controls (a) the § 102(b) window and (b) whether US 8,426,450 can be § 102(e) art (it likely cannot, if the inventive entity is the same). Establish the priority chain before litigating dates.
6. Whatever the claim set says, note the internal contradiction in the specification's salt story: the '772 claims/describes a zwitterionic "(phosphonooxy)methyl)piperazin-1-ium" (the claimed compound) while the invention's headline stability argument is about a chloride hydrochloride salt, and the claim-drafting in the family's salt patents (US 11,312,698, US 10,208,073) carries the degradant-percentage limitation. That mismatch is an argument in itself for whoever is challenging, and a nexus problem for whoever is defending.

Bottom line

On the compound claim, this is a strong § 103 case built on as few as two references. PA-1 (Krise/Stella 1999, J. Med. Chem.) expressly phosphonooxymethylates a 4-methylpiperazine nitrogen on loxapine; PA-5 (Roche '375) provides netupitant, whose only relevant quaternization site is an identical 4-methylpiperazine nitrogen. PA-2 and PA-3 supply the solubility gain and the rapid, quantitative in vivo reversion; PA-4 claims the genus with an "organic or inorganic cation"; PA-8 expressly generalises OMP prodrugs to "other drug classes with limited solubility"; PA-9 shows the same move already commercialised for an IV NK1-antagonist CINV product; and the '772's own Background admits the solubility/PK problem (PA-6) and admits netupitant was in clinical development. The remaining ~10 dependent claims add nothing beyond species already present in PA-5 or cations already present in PA-4.

The one genuine defensive foothold is the salt-form/stability story, and it only bites if claim 1 is limited to the chloride hydrochloride rather than to the GA1 zwitterion or "a pharmaceutically acceptable salt or adduct thereof." That is why the claim text — still unretrieved — is the threshold task before any of this is relied on.